Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DENTSPLY SIRONA Inc. (Nasdaq: XRAY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, strategic reviews and key governance decisions.
In its Form 8-K filings, Dentsply Sirona reports results of operations and financial condition for recent quarters, including segment and geographic performance, non-GAAP metrics and information about goodwill and intangible asset impairments. The company also files 8-Ks to disclose changes in executive officers, retention equity incentive awards, formation of board-level committees and updates on matters such as the conclusion of an SEC Division of Enforcement investigation without enforcement action.
Other filings referenced by the company, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, contain detailed risk factors, financial statements and management discussion that are incorporated by reference in forward-looking statements. These documents provide context on how Dentsply Sirona views risks related to its dental products, technologies, segments and global operations.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the significance of each document in straightforward language. Real-time updates from EDGAR help users follow new 8-Ks reporting quarterly earnings, leadership transitions or strategic portfolio decisions, as well as periodic reports like 10-K and 10-Q when available. For those monitoring governance and incentives, filings also describe compensation arrangements, retention grants and board committee structures. This page is a focused resource for understanding how Dentsply Sirona communicates material information, manages regulatory obligations and frames risks and opportunities in its official SEC documents.
AQR Capital Management Holdings, LLC and its wholly owned subsidiary AQR Capital Management, LLC report beneficial ownership of DENTSPLY SIRONA Inc. common stock. They disclose beneficially owning 4,898,136 shares, representing 2.45% of the outstanding common stock.
The firms report shared voting and dispositive power over all of these shares and no sole voting or dispositive power. They certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of DENTSPLY SIRONA.
DENTSPLY SIRONA Inc. director Donald Zurbay reported a stock-based award from the company. On 01/26/2026, he was granted 6,871 shares of common stock at a price of $0, reflecting an equity grant rather than a purchase.
According to the footnote, the award consists entirely of Restricted Stock Units that vest in full one year from the grant date, after which the restrictions lapse. Following this grant, Zurbay beneficially owns 6,871 shares directly, aligning his interests more closely with shareholders through additional equity compensation.
DENTSPLY SIRONA Inc. director Donald J. Zurbay filed an initial ownership report on Form 3 stating that he does not beneficially own any company securities. The filing confirms his status as a director and notes, in the remarks section, that no securities are beneficially owned.
DENTSPLY SIRONA Inc. reported that it has entered into new non-exclusive distribution agreements with Patterson for the distribution of its dental equipment in the United States. The company disclosed this development through a current report and attached a press release as Exhibit 99.1 describing the arrangements. The disclosure is made under Regulation FD and is treated as information that is furnished rather than filed under the securities laws, which limits how it is incorporated into other company reports.
DENTSPLY SIRONA Inc. director Janet S. Vergis reported an automatic increase in her equity holdings through dividend equivalents on restricted stock units (RSUs). On January 9, 2026, she was credited with 200.899 shares of common stock at a price of $0, recorded as an acquisition under code A.
These shares represent dividends on existing RSUs, paid in the form of additional RSUs that follow the same vesting schedule as the underlying awards. Each RSU converts into one share of common stock. Following this transaction, Vergis directly beneficially owns 44,501.066 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Leslie F. Varon reported an acquisition of company equity tied to existing restricted stock units (RSUs). On 01/09/2026, Varon received 198.141 shares of common stock at a price of $0, reflecting dividends on previously granted RSUs that were paid in the form of additional RSUs. These dividend-equivalent RSUs carry the same vesting terms as the underlying awards and will vest at the same time. After this transaction, Varon directly beneficially owned 57,541.066 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. executive Daniel T. Scavilla, the company’s President, CEO and a director, reported acquiring additional common stock through equity compensation. On January 9, 2026, he received 245.816 shares of common stock at $0 per share, recorded as an acquisition. After this transaction, he directly beneficially owned 17,944.546 common shares.
According to the footnote, these shares represent dividends on restricted stock units (RSUs) paid in the form of additional RSUs, which follow the same vesting schedule as the underlying awards. The dividend RSUs vest at the same time as the related RSUs, and each RSU will convert into one share of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky reported routine equity awards tied to his board service. On January 9, 2026, he acquired 395.158 shares of common stock at $0, representing dividends paid on his existing restricted stock units (RSUs). These dividend RSUs follow the same vesting schedule as the underlying RSUs and each RSU converts into one share of common stock. After this transaction, he beneficially owned 28,846.534 common shares directly.
On the same date, he also acquired 153.7009 phantom stock units under the directors' deferred compensation program at an assigned value of $12.22 per unit, increasing his directly held phantom stock balance to 14,535.2138 units. Each phantom stock unit is economically equivalent to one share of common stock and becomes payable in common stock when his service as a director ends.
DENTSPLY SIRONA Inc. director Gregory T. Lucier reported an automatic award of additional common stock tied to existing restricted stock units. On 01/09/2026, an entity described as a family partnership associated with him received 341.114 shares of common stock at a price of $0, reflecting dividends on his restricted stock units that were paid in the form of additional RSUs.
After this transaction, the family partnership held 24,901.284 common shares indirectly. Separately, an IRA associated with Gregory Lucier held 21,000 common shares indirectly, while his direct common stock holdings were reported as zero. The footnote explains that these dividend RSUs follow the same vesting schedule as the underlying RSU awards and each RSU converts into one share of common stock.
DENTSPLY SIRONA Inc. senior executive Robert Anthony Johnson, SVP and Chief Supply Chain Officer, reported routine equity compensation grants. On January 9, 2026, he acquired 641.625 shares of common stock at a price of
On the same date, he was credited with 40.22 phantom stock units under the Supplemental Executive Retirement Plan at a reference price of